Biomedical
Hereditary non-polyposis colorectal cancer (HNPCC), also known as Lynch syndrome, is an inherited condition that increases the risk of developing colorectal and other types of cancer. It is caused by mutations in one of several genes involved in DNA repair, including MLH1, MSH2, MSH6, PMS2, and EPCAM. These genes are responsible for repairing errors that occur during DNA replication, and when they are mutated, errors can accumulate in the DNA, leading to the development of cancer.
HNPCC is the most common inherited cause of colorectal cancer, accounting for approximately 3-5% of all cases. In addition to colorectal cancer, individuals with HNPCC also have an increased risk of developing other types of cancer, including endometrial, ovarian, gastric, pancreatic, and urinary tract cancers. The inheritance pattern of HNPCC is autosomal dominant, meaning that a person only needs to inherit one copy of the mutated gene from a parent to be at risk for developing the condition. If one parent has the mutation, there is a 50% chance that their child will inherit it as well.
Diagnosing HNPCC typically involves genetic testing to identify mutations in one of the genes associated with the condition. If a mutation is identified, family members can be tested to determine if they have inherited the mutation and are at increased risk for developing cancer. For individuals who have a family history of HNPCC but do not have a known mutation, screening and surveillance may still be recommended.
Efforts to raise awareness about HNPCC and the importance of genetic testing and counseling are crucial for early diagnosis and management. Education campaigns and outreach to healthcare providers and communities can promote awareness and reduce the stigma associated with genetic testing. Research into the genetics and management of HNPCC is essential for developing new treatment options and improving outcomes for affected individuals.
HNPCC is an inherited condition that increases the risk of developing colorectal and other types of cancer due to mutations in genes involved in DNA repair. Genetic testing, counseling, regular surveillance, and targeted therapies are important for managing the condition. Public health efforts to raise awareness and promote early detection and prevention can significantly reduce the burden of HNPCC and improve outcomes for affected individuals and families.
HNPCC, also known as Lynch syndrome, is an inherited condition that increases the risk of colorectal and other types of cancer due to mutations in DNA repair genes.
The primary genes associated with HNPCC include MLH1, MSH2, MSH6, PMS2, and EPCAM, all of which play roles in DNA repair mechanisms.
Individuals with HNPCC are at increased risk of developing colorectal, endometrial, ovarian, gastric, pancreatic, and urinary tract cancers.
HNPCC follows an autosomal dominant inheritance pattern, meaning a mutation in one gene copy is sufficient to increase cancer risk.
Diagnosis involves genetic testing to detect mutations in HNPCC-related genes, often guided by family history and clinical criteria.
Management includes regular cancer screening, genetic counseling, prophylactic surgery, and targeted therapies such as immune checkpoint inhibitors.
Public health efforts include awareness campaigns, improving access to genetic testing, training healthcare providers, and supporting research into prevention and treatment.
Show by month | Manuscript | Video Summary |
---|---|---|
2025 February | 7 | 7 |
2025 January | 58 | 58 |
2024 December | 42 | 42 |
2024 November | 44 | 44 |
2024 October | 45 | 45 |
Total | 196 | 196 |
Show by month | Manuscript | Video Summary |
---|---|---|
2025 February | 7 | 7 |
2025 January | 58 | 58 |
2024 December | 42 | 42 |
2024 November | 44 | 44 |
2024 October | 45 | 45 |
Total | 196 | 196 |